Abstract
Rejection after kidney transplantation remains an important cause of allograft failure that markedly impacts morbidity. Cytokines are a major player in rejection, and we, therefore, explored the impact of interleukin-6 (IL6) and IL-6 receptor (IL6R) gene polymorphisms on the occurrence of rejection after renal transplantation. We performed an observational cohort study analyzing both donor and recipient DNA in 1,271 renal transplant-pairs from the University Medical Center Groningen in The Netherlands and associated single nucleotide polymorphisms (SNPs) with biopsy-proven rejection after kidney transplantation. The C-allele of the IL6R SNP (Asp358Ala; rs2228145 A>C, formerly rs8192284) in donor kidneys conferred a reduced risk of rejection following renal transplantation (HR 0.78 per C-allele; 95%-CI 0.67–0.90; P=0.001). On the other hand, the C-allele of the IL6 SNP (at position-174 in the promoter; rs1800795 G>C) in donor kidneys was associated with an increased risk of rejection for male organ donors (HR per C-allele 1.31; 95%-CI 1.08–1.58; P=0.0006), but not female organ donors (P=0.33). In contrast, neither the IL6 nor IL6R SNP in the recipient showed an association with renal transplant rejection. In conclusion, donor IL6 and IL6R genotypes but not recipient genotypes represent an independent prognostic marker for biopsy-proven renal allograft rejection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is in accordance with the declaration of Helsinki and all patients provided written informed consent. The medical ethics committee of the University Medical Center Groningen approved the study under file number METc 2014/077.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
For original data, please contact f.poppelaars{at}umcg.nl
Abbreviations
- AUC
- Area under the curve
- ABMR
- Antibody mediated rejection
- CIT
- Cold ischemia time
- DBD
- Donation after circulatory death
- DCD
- Donation after brain death
- DGF
- Delayed graft function
- ESKD
- End-stage kidney disease
- Gp130
- Glycoprotein 130 (gp130)
- HLA
- Human leukocyte antigen
- HR
- Hazard ratio
- IDI
- Integrated discrimination improvement
- IL 6
- Interleukin 6
- IL6
- Interleukin 6 gene
- IL-6R
- Interleukin 6 receptor
- IL6R
- Interleukin 6 receptor gene
- JAK
- Janus kinase (JAK)
- mIL-6R
- Membrane-bound interleukin 6 receptore
- PRA
- Panel-reactive antibody
- STAT
- Signal transducer and activator of transcription
- sIL-6R
- Soluble Interleukin 6 receptor
- SNP
- Single-nucleotide polymorphism
- WIT
- Warm ischemia time
